Welcome to our dedicated page for Remegen news (Ticker: REGMY), a resource for investors and traders seeking the latest updates and insights on Remegen stock.
News and updates for RemeGen Co., Ltd. (REGMY) focus heavily on its clinical and regulatory progress in biologic drug development. Company announcements highlight data from Phase II and Phase III trials in autoimmune diseases, oncology, and ophthalmology, along with licensing agreements and global development milestones. Investors and observers can use this news stream to follow how RemeGen advances its pipeline from research to commercialization.
In autoimmune diseases, RemeGen frequently reports results for telitacicept, its BLyS/APRIL dual-target fusion protein. Recent news includes Phase III data in generalized myasthenia gravis and primary Sjögren's syndrome in China, regulatory approvals and submissions, and orphan drug and fast track designations from regulators such as the FDA and EMA. These releases often detail efficacy endpoints like MG-ADL and QMG scores and discuss guideline and consensus recognition in China.
Oncology-related news centers on disitamab vedotin (DV), a HER2-targeted antibody-drug conjugate, and other candidates such as RC148. RemeGen publishes updates on Phase II and Phase III trials in HER2-expressing gastric cancer, urothelial carcinoma, and muscle-invasive bladder cancer, including presentations at major meetings like ASCO and ASCO GU. These articles typically describe progression-free survival, overall survival, pathological complete response rates, and safety profiles.
In ophthalmology, news items cover RC28-E and its clinical performance in diabetic macular edema and wet age-related macular degeneration, as well as a licensing agreement with Santen for specified Asian territories. Visitors to this page can review RemeGen’s latest scientific presentations, regulatory milestones, and partnership announcements in one place and may wish to check back regularly for new clinical data and corporate developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.